Systemic tissue repair & gut-immune axis vs innate antimicrobial defense — complete head-to-head comparison of mechanisms, wound healing, dosing protocols, stacking guide, and decision tree.
BPC-157 and LL-37 both contribute to wound healing and tissue protection, but through entirely different mechanisms. BPC-157 is a systemic tissue repair peptide — it drives angiogenesis, collagen synthesis, and fibroblast activation through EGR-1 upregulation, making it the most studied peptide for musculoskeletal injury, gut healing, and post-surgical recovery. LL-37 is a cathelicidin antimicrobial peptide — it provides the innate immune defense layer at wound sites, directly killing bacteria and viruses through membrane disruption, preventing biofilm formation, and modulating the acute inflammatory response.
The practical implication is that these compounds address different phases of the healing process. LL-37 is more relevant in the acute, infection-prone phase of wound healing; BPC-157 is more relevant in the repair and regeneration phase. For research protocols targeting infected wounds, post-surgical recovery with infection risk, or gut health with concurrent gut pathogen exposure, stacking both compounds provides mechanistically complementary coverage with no known interaction concerns.
Research Disclaimer: All content on this page is for educational and research purposes only. These compounds are not FDA-approved for the indications discussed. Always consult a qualified healthcare professional before considering any peptide protocol.
Body Protection Compound-157 · Gastric Pentadecapeptide
BPC-157 is a synthetic 15-amino acid peptide (GEPPPGKPADDAGLV) derived from a protective protein found in human gastric juice. Its primary mechanisms center on tissue repair and angiogenesis: it upregulates EGR-1, a transcription factor that drives collagen synthesis, tendon cell proliferation, and vascular endothelial growth. It also activates the NO-cGMP pathway for vasodilation and tissue perfusion, and directly upregulates VEGF for new blood vessel formation. Its gastric mucosal protective effects make it the most studied peptide for IBD, leaky gut, and GI injury repair.
Cathelicidin · Human Antimicrobial Peptide · 37 Amino Acids
LL-37 is the only known human cathelicidin — a 37-amino acid antimicrobial peptide produced by neutrophils, macrophages, mast cells, and epithelial cells. Its primary antimicrobial mechanism is membrane disruption: it forms amphipathic alpha-helices that insert into and destabilize bacterial and viral lipid membranes. Beyond direct antimicrobial activity, LL-37 activates TLR4 and FPRL1 receptors to modulate inflammatory cytokine production, promotes keratinocyte migration for wound healing, stimulates angiogenesis via VEGF upregulation, and has strong anti-biofilm activity against MRSA and Pseudomonas aeruginosa.
| Category | BPC-157 | LL-37 |
|---|---|---|
| Primary Mechanism | EGR-1 upregulation, angiogenesis, NO-cGMP pathway, collagen synthesis | Membrane disruption, TLR4/FPRL1 signaling, keratinocyte migration, VEGF upregulation |
| Primary Application | Tissue repair, injury healing, gut health, musculoskeletal recovery | Antimicrobial defense, wound infection prevention, innate immune modulation |
| Wound Healing | Excellent — angiogenesis, collagen synthesis, fibroblast activation | Significant — keratinocyte migration, anti-biofilm, infection prevention |
| Antimicrobial Activity | Minimal — not a primary antimicrobial peptide | Excellent — direct membrane disruption; broad-spectrum |
| Gut Health | Excellent — gastric mucosal protection, IBD, leaky gut | Moderate — intestinal epithelial antimicrobial; gut-immune axis |
| Anti-Biofilm | Minimal | Strong — disrupts biofilm matrix; studied for MRSA, Pseudomonas |
| Immune Modulation | Moderate anti-inflammatory; macrophage modulation | Biphasic — pro-inflammatory in acute phase; anti-inflammatory in resolution |
| Neurological Effects | Dopamine/serotonin modulation; studied for depression, TBI | Minimal direct neurological effects |
| Typical Dose | 250–500 mcg/day | 100–500 mcg/day |
| Administration | SubQ injection (preferred) or oral | SubQ injection (preferred) or topical |
| Cycle Length | 4–12 weeks | 4–8 weeks |
| Evidence Level | Extensive preclinical (rodent); limited human data | Extensive in vitro; growing in vivo; limited human trials |
| Safety Profile | Favorable in preclinical; no serious adverse events reported | Favorable in preclinical; limited human safety data |
| Stackable With | TB-500, Thymosin Alpha-1, LL-37, GHK-Cu, CJC-1295/Ipamorelin | BPC-157, Thymosin Alpha-1, VIP, GHK-Cu |
Research Verdict
Complementary Wound Healing Mechanisms
BPC-157 and LL-37 address different phases of wound healing and tissue protection. BPC-157 is the clear choice for tissue repair, musculoskeletal recovery, and gut healing. LL-37 is the clear choice for antimicrobial defense, wound infection prevention, and anti-biofilm research. For infected wound healing protocols, the compounds are mechanistically complementary: LL-37 handles the antimicrobial and inflammatory phase while BPC-157 drives the repair and regeneration phase.
BPC-157 drives tissue repair, angiogenesis, and collagen synthesis at the wound site while LL-37 provides antimicrobial protection, prevents biofilm formation, and modulates the acute inflammatory response. LL-37 can be applied topically at the wound site while BPC-157 is administered systemically via SubQ injection.
For research subjects with both gut pathology (IBD, leaky gut) and gut-associated infection or dysbiosis. BPC-157 provides direct gastric mucosal protection and gut healing via EGR-1 upregulation. LL-37 is naturally produced by intestinal epithelial cells and has antimicrobial activity against gut pathogens. The combination addresses both structural gut healing and antimicrobial defense.
For research protocols targeting tissue repair, innate antimicrobial defense, and adaptive immune support simultaneously. BPC-157 handles tissue repair and gut healing; LL-37 provides innate antimicrobial barrier function; Thymosin Alpha-1 strengthens adaptive T-cell immunity. This three-compound stack covers tissue repair, innate immunity, and adaptive immunity with no known mechanism-based conflicts.
| Research Goal | Recommended | Rationale |
|---|---|---|
| Tendon / ligament injury repair | BPC-157 | Direct EGR-1 upregulation, angiogenesis, collagen synthesis |
| Gut healing (IBD, leaky gut, ulcers) | BPC-157 | Gastric mucosal protection; primary indication |
| Direct antimicrobial / bacterial infection | LL-37 | Direct membrane disruption; broad-spectrum antimicrobial |
| Wound infection prevention | LL-37 | Antimicrobial barrier + anti-biofilm activity at wound site |
| Wound tissue repair (post-infection) | BPC-157 | Angiogenesis + collagen synthesis; most studied for tissue repair |
| Anti-biofilm (drug-resistant organisms) | LL-37 | Disrupts biofilm matrix; studied for MRSA and Pseudomonas |
| Neurological support (TBI, depression) | BPC-157 | Dopamine/serotonin modulation; studied in TBI models |
| Infected wound healing (combined) | Stack both | LL-37 (infection) + BPC-157 (repair) = complete wound healing protocol |
| Musculoskeletal recovery | BPC-157 | Primary indication; most extensive preclinical data |
BPC-157 is a gastric pentadecapeptide focused on systemic tissue repair, angiogenesis, gut healing, and musculoskeletal recovery via EGR-1 upregulation and NO-cGMP pathway activation. LL-37 is a cathelicidin antimicrobial peptide that operates in innate immunity — it directly disrupts bacterial and viral membranes, modulates inflammatory cytokines via TLR4/FPRL1 signaling, and promotes wound healing via keratinocyte migration. BPC-157 is primarily a repair peptide; LL-37 is primarily an antimicrobial and innate immune peptide.
Yes — they are highly complementary for wound healing and infection recovery protocols. BPC-157 drives tissue repair, angiogenesis, and collagen synthesis at the wound site while LL-37 provides antimicrobial protection, prevents biofilm formation, and modulates the acute inflammatory response. There is no known mechanism-based conflict between the two compounds.
Both contribute to wound healing through different mechanisms. BPC-157 drives the repair phase: angiogenesis, collagen synthesis, and fibroblast activation via EGR-1 upregulation. LL-37 drives the protective phase: antimicrobial barrier, anti-biofilm activity, and keratinocyte migration. In infected wound models, LL-37 is more directly applicable for infection clearance; BPC-157 is more applicable for accelerating tissue repair after infection is controlled. The optimal protocol often combines both.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a protective protein in human gastric juice. Its primary mechanisms include: upregulation of EGR-1 which drives collagen synthesis and angiogenesis; activation of the NO-cGMP pathway for vasodilation and tissue perfusion; upregulation of VEGF for new blood vessel formation; modulation of the dopamine and serotonin systems; and direct gastric mucosal protective effects.
LL-37 is a 37-amino acid cathelicidin peptide. Its primary antimicrobial mechanism is membrane disruption — it forms amphipathic helices that insert into and destabilize bacterial and viral lipid membranes. It also activates TLR4 and FPRL1 receptors to modulate inflammatory cytokine production, promotes keratinocyte migration and proliferation for wound healing, stimulates angiogenesis via VEGF upregulation, and has anti-biofilm activity against drug-resistant organisms including MRSA and Pseudomonas aeruginosa.
BPC-157 is significantly more studied for gut health. It provides direct gastric mucosal protection, promotes healing of IBD, leaky gut syndrome, and gastric ulcers via EGR-1 upregulation and NO-cGMP pathway activation. LL-37 has some gut-immune axis activity but gut healing is not its primary indication. For gut-specific research, BPC-157 is the more appropriate choice.
Both have substantial preclinical research bases. BPC-157 has extensive rodent model data across multiple injury, gut healing, and neurological models. LL-37 has extensive in vitro data for antimicrobial activity and growing in vivo data for wound healing and immune modulation. Neither has significant human clinical trial data.
Choose BPC-157 if your research goal is tissue repair, injury healing, gut health, musculoskeletal recovery, or neurological support. Choose LL-37 if your research goal is direct antimicrobial activity, wound infection prevention, anti-biofilm research, or innate immune barrier support. For wound healing protocols where both repair and infection prevention are relevant, stacking both compounds provides mechanistically complementary coverage.
Purgo Labs carries pharmaceutical-grade BPC-157 and LL-37 with third-party COA verification. Use code HEALTH for 15% off.
Visit Purgo LabsAffiliate disclosure: Compound Review may earn a commission on qualifying purchases.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.